Alison Howarth joined us in February 2016 from the University of Oxford where she held the position of Research Assistant/Lab Manager. She has a BSc (Honours) in Zoology from the University of Wales and an MSc from the LiverpoolSchool of Tropical Medicine. Alison’s PhD is funded by the Ollie Young Foundation. She is currently carrying out research into “The anti-neoplastic effects of repurposed drugs and PI3 kinase inhibitors on paediatric GBM and DIPG”.
For more information on Alison’s project click here.
Katie graduated from the University of Portsmouth with a Bachelor’s degree (Hons) in Forensic Biology. She undertook her Master’s degree in Biomedicine and completed her project in Professor Arthur Butt’s lab, investigating the regulation of stem cells via the inhibition of GSK3β. Katie undertook four months of volunteer work in the Neuro-oncology labs working on the role of MMP-1 in Glioblastoma Multiforme in the summer of 2013 and was subsequently appointed as a specialist technician, funded by Children with Cancer UK, involved in the investigation of GD3/GD3A in paediatric Medulloblastoma. Katie will start her PhD, part-funded by the Ollie Young Foundation, in October 2016. Her research will help identify key host/tumour interactions and processes that drive DIPG growth that will lead to improved therapeutics
Chiara held the position of Junior Researcher at the Instituto Superiore di Sanita before joining the Cardiff/Portsmouth team in 2014. She is working on the “Role of Phospho-Caveolin1 in GBM stem cell differentiation and biological structures”. Chiara has an MA in Medial Biotechnologies from the Faculty of Medicine at the Catholic University of Rome.
Cátia Sofia Neves Neto
Cátia has a BSc in Nuclear Medicine from the University of Porto, Portugal and an MSc in Molecular Medicine and Oncology from the Faculty of Medicine, University of Porto, Portugal. Before joining the Cardiff/Portsmouth team she carried out a project on the “Role of activated microglia in the acquisition of a stem-like phenotype in glioblastoma”. She is currently carrying out research into the “Role of Phospho-Caveolin1 in GBM radio and chemo sensitising”.
Joshua Pearson joined the Nottingham Trent/Portsmouth team in 2016. He has a BSc in Medical Neuroscience and an MSc in Cellular and Molecular Neuroscience from the University of Sussex. He is currently investigating HAGE-targeted immunotherapy for GBM.